# 2025-08137: FDA Shuffles Animal Meds List for Clarity

2025-08137, New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-05-09, effective 2025-05-09; PRIA reads it as touching household money (as of 2026-10-16).

- Canonical: https://policyrisk.com/federal-register/2025-08137
- As of: 2026-10-16
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08137
- Title: New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 19623
- Published: 2025-05-09
- Effective: 2025-05-09
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-16

## In one line

FDA Shuffles Animal Meds List for Clarity

## Summary

The FDA just updated the rules for new animal drugs approved in early 2025, making sure everything is clear and up-to-date. This affects drug makers, vets, and pet owners by confirming which new medicines are officially good to go. The changes kick in right away on May 9, 2025, with no extra costs but better info and transparency for everyone.

## Abstract

The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs), abbreviated new animal drug applications (ANADAs), and conditionally approved new animal drug applications (CNADAs) during January, February, and March 2025. The animal drug regulations are also being amended to improve their accuracy and readability.

## Effects PRIA read

- New sirolimus product for cats: benefit, medium. FDA added Sec. 516.2106 for sirolimus: sustained‑release tablets containing 0.4, 1.2, or 2.4 mg sirolimus are specified, and the drug is approved for use in cats for management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). The label directs oral administrati…
- FDA approves two generic animal drugs: benefit, low. FDA approved two generic animal drug applications during January–March 2025: EPRIMECTIN Pour‑On (eprinomectin) as a generic copy of NADA 141-079 (file no. 200-626) on January 13, 2025, and tulathromycin injectable solution as a generic copy of NADA 141-244 (file no. 200-742) on February 25, 2025.
- Withdrawal of SEDAZINE (xylazine) approval: cost, low. Approval of ANADA 200-088 for SEDAZINE (xylazine hydrochloride) Injectable Solution was withdrawn at the sponsor's request because the product is no longer manufactured or marketed; the withdrawal was effective December 10, 2023. The record and animal drug regulations are amended to reflect this wi…
- Approval documents and reviews posted online: benefit, low. For approvals during January, February, and March 2025 that required safety/effectiveness review or environmental review, FDA states that documentation (NEPA reviews) and FOIA Summaries, along with marketing exclusivity and patent information, may be obtained at Animal Drugs @ FDA: https://animaldr…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08137 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/09/2025-08137/new-animal-drugs-approval-of-new-animal-drug-applications-withdrawal-of-approval-of-new-animal-drug)
- [2025-08137 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-09/pdf/2025-08137.pdf)

## Related
- [Previous: 2025-08129, Federal Management Regulation; Nondiscrimination Clarification in the Federal W…](https://policyrisk.com/federal-register/2025-08129)
- [Next: 2025-08143, Medical Devices; Immunology and Microbiology Devices; Classification of the DNA…](https://policyrisk.com/federal-register/2025-08143)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08137 (as of 2026-10-16).
